Neonatal CMV-Ganciclovir Follow-up Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00031421|
Recruitment Status : Completed
First Posted : March 7, 2002
Last Update Posted : August 12, 2011
|Condition or disease|
|Study Type :||Observational|
|Enrollment :||8 participants|
|Observational Model:||Case Control|
|Official Title:||A Follow-up Assessment of Subjects Who Received Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) During the Phase I/II Study to Evaluate the Safety and Efficacy of Ganciclovir Treatment for Congenital Cytomegalovirus (CMV) Infections|
|Study Start Date :||September 2001|
|Study Completion Date :||November 2005|
16 received ganciclovir at 8 mg/kg/day in the previous study.
31 received ganciclovir at 12 mg/kg/day in the previous study.
- Sexual Development. [ Time Frame: Analysis. ]
- Pubertal Status. [ Time Frame: Analysis. ]
- Cancer Incidence. [ Time Frame: Analysis. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00031421
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35233|